Genmab — Marts 2018

Bulder

E L if you look at the changes in the study from may last year, you can see that they have changed from "terminated" to "active not recruiting". So Novartis decided to finish the study without genmab telling us about it.

bibob

MJ

Bulder

In other words: GSK terminated but Novartis resumed the study.

E_L

Bulder, i was reading that just the opposite; as if Novartis kept it alive longer without telling us and was wondering why they would have done that

E_L

ok, that is what i was reading

E_L

lol MJ

Bulder

If I was Bibob I would try with 3 Heineken.

JKY_VH

Helge_LarsenPI-redaktør

Samme mønster som seneste dage.Rolig handel, hvor A/B køber sig fra netto salg til nettokøb.
f

Helge_LarsenPI-redaktør

Et typisk "basedannelsesmønster".

Helge_LarsenPI-redaktør

Vil tro at et brud på årets top på 1.278 vil udløse et klart købssignal.

Mcjean

20 bogstaver Helge bravo, det kalder jeg et forum med høje lixtal, man får noget for pengene:-)

Helge_LarsenPI-redaktør

Tak...Jeg øver mig.

Bulder

Looking a bit closer into the ofa-study mentioned above, I can see that it was actually Novartis that terminated the study after acquiring the rights to ofa. They did that in May 2016. Nevertheless they resumed the study in May last year.

gentogen

AQpropos OFA så skrev de maj 16 på clinical trials "Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration". Antallet af patienter er det samme til slut som dengang, så de åbenbart valgt at følge patienterne i en ydvidet periode.

Bulder

Ja, for de ændrede bare fra terminated til active not recruiting.

Bulder

Men nu hvor det er completed, kunne det da være udmærket med en offentliggørelse af resultaterne. Helge, skriver du til Rachel?

Helge_LarsenPI-redaktør

Hej Bulder..Sidder i møde. Prøv selv på r.gravesen.com.

OHW

Øhh..vi har vel ingen luk i år over 1260,5 eller ser jeg fejl?

pauly

Det har du vist ret i